Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.
Identifieur interne : 000328 ( Main/Exploration ); précédent : 000327; suivant : 000329Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.
Auteurs : Jeffrey C. Kwong [Canada] ; Priya P. Vasa ; Michael A. Campitelli ; Steven Hawken ; Kumanan Wilson ; Laura C. Rosella ; Therese A. Stukel ; Natasha S. Crowcroft ; Allison J. Mcgeer ; Lorne Zinman ; Shelley L. DeeksSource :
- The Lancet. Infectious diseases [ 1474-4457 ] ; 2013.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Canada (épidémiologie), Facteurs de risque, Femelle, Grippe humaine (), Hospitalisation, Humains, Incidence, Jeune adulte, Mâle, Saisons, Sujet âgé, Syndrome de Guillain-Barré (), Syndrome de Guillain-Barré (épidémiologie), Vaccination (), Vaccination (effets indésirables), Vaccins antigrippaux (effets indésirables), Vaccins inactivés (effets indésirables).
- MESH :
- effets indésirables : Vaccination, Vaccins antigrippaux, Vaccins inactivés.
- épidémiologie : Canada, Syndrome de Guillain-Barré.
- Adolescent, Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Grippe humaine, Hospitalisation, Humains, Incidence, Jeune adulte, Mâle, Saisons, Sujet âgé, Syndrome de Guillain-Barré, Vaccination.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Canada (epidemiology), Female, Guillain-Barre Syndrome (chemically induced), Guillain-Barre Syndrome (epidemiology), Hospitalization, Humans, Incidence, Influenza Vaccines (adverse effects), Influenza, Human (prevention & control), Male, Middle Aged, Risk Factors, Seasons, Vaccination (adverse effects), Vaccination (statistics & numerical data), Vaccines, Inactivated (adverse effects), Young Adult.
- MESH :
- chemical , adverse effects : Influenza Vaccines, Vaccines, Inactivated.
- geographic , epidemiology : Canada.
- adverse effects : Vaccination.
- chemically induced : Guillain-Barre Syndrome.
- epidemiology : Guillain-Barre Syndrome.
- prevention & control : Influenza, Human.
- statistics & numerical data : Vaccination.
- Adolescent, Adult, Aged, Female, Hospitalization, Humans, Incidence, Male, Middle Aged, Risk Factors, Seasons, Young Adult.
Abstract
BACKGROUND
The possible risk of Guillain-Barré syndrome from influenza vaccines remains a potential obstacle to achieving high vaccination coverage. However, influenza infection might also be associated with Guillain-Barré syndrome. We aimed to assess the risk of Guillain-Barré syndrome after seasonal influenza vaccination and after influenza-coded health-care encounters.
METHODS
We used the self-controlled risk interval design and linked universal health-care system databases from Ontario, Canada, with data obtained between 1993 and 2011. We used physician billing claims for influenza vaccination and influenza-coded health-care encounters to ascertain exposures. Using fixed-effects conditional Poisson regression, we estimated the relative incidence of hospitalisation for primary-coded Guillain-Barré syndrome during the risk interval compared with the control interval.
FINDINGS
We identified 2831 incident admissions for Guillain-Barré syndrome; 330 received an influenza vaccine and 109 had an influenza-coded health-care encounter within 42 weeks before hospitalisation. The risk of Guillain-Barré syndrome within 6 weeks of vaccination was 52% higher than in the control interval of 9-42 weeks (relative incidence 1·52; 95% CI 1·17-1·99), with the greatest risk during weeks 2-4 after vaccination. The risk of Guillain-Barré syndrome within 6 weeks of an influenza-coded health-care encounter was greater than for vaccination (15·81; 10·28-24·32). The attributable risks were 1·03 Guillain-Barré syndrome admissions per million vaccinations, compared with 17·2 Guillain-Barré syndrome admissions per million influenza-coded health-care encounters.
INTERPRETATION
The relative and attributable risks of Guillain-Barré syndrome after seasonal influenza vaccination are lower than those after influenza illness. Patients considering immunisation should be fully informed of the risks of Guillain-Barré syndrome from both influenza vaccines and influenza illness.
FUNDING
Canadian Institutes of Health Research.
DOI: 10.1016/S1473-3099(13)70104-X
PubMed: 23810252
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.</title><author><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada. jeff.kwong@utoronto.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Vasa, Priya P" sort="Vasa, Priya P" uniqKey="Vasa P" first="Priya P" last="Vasa">Priya P. Vasa</name></author><author><name sortKey="Campitelli, Michael A" sort="Campitelli, Michael A" uniqKey="Campitelli M" first="Michael A" last="Campitelli">Michael A. Campitelli</name></author><author><name sortKey="Hawken, Steven" sort="Hawken, Steven" uniqKey="Hawken S" first="Steven" last="Hawken">Steven Hawken</name></author><author><name sortKey="Wilson, Kumanan" sort="Wilson, Kumanan" uniqKey="Wilson K" first="Kumanan" last="Wilson">Kumanan Wilson</name></author><author><name sortKey="Rosella, Laura C" sort="Rosella, Laura C" uniqKey="Rosella L" first="Laura C" last="Rosella">Laura C. Rosella</name></author><author><name sortKey="Stukel, Therese A" sort="Stukel, Therese A" uniqKey="Stukel T" first="Therese A" last="Stukel">Therese A. Stukel</name></author><author><name sortKey="Crowcroft, Natasha S" sort="Crowcroft, Natasha S" uniqKey="Crowcroft N" first="Natasha S" last="Crowcroft">Natasha S. Crowcroft</name></author><author><name sortKey="Mcgeer, Allison J" sort="Mcgeer, Allison J" uniqKey="Mcgeer A" first="Allison J" last="Mcgeer">Allison J. Mcgeer</name></author><author><name sortKey="Zinman, Lorne" sort="Zinman, Lorne" uniqKey="Zinman L" first="Lorne" last="Zinman">Lorne Zinman</name></author><author><name sortKey="Deeks, Shelley L" sort="Deeks, Shelley L" uniqKey="Deeks S" first="Shelley L" last="Deeks">Shelley L. Deeks</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23810252</idno><idno type="pmid">23810252</idno><idno type="doi">10.1016/S1473-3099(13)70104-X</idno><idno type="wicri:Area/Main/Corpus">000345</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000345</idno><idno type="wicri:Area/Main/Curation">000345</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000345</idno><idno type="wicri:Area/Main/Exploration">000345</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.</title><author><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada. jeff.kwong@utoronto.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Institute for Clinical Evaluative Sciences, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Vasa, Priya P" sort="Vasa, Priya P" uniqKey="Vasa P" first="Priya P" last="Vasa">Priya P. Vasa</name></author><author><name sortKey="Campitelli, Michael A" sort="Campitelli, Michael A" uniqKey="Campitelli M" first="Michael A" last="Campitelli">Michael A. Campitelli</name></author><author><name sortKey="Hawken, Steven" sort="Hawken, Steven" uniqKey="Hawken S" first="Steven" last="Hawken">Steven Hawken</name></author><author><name sortKey="Wilson, Kumanan" sort="Wilson, Kumanan" uniqKey="Wilson K" first="Kumanan" last="Wilson">Kumanan Wilson</name></author><author><name sortKey="Rosella, Laura C" sort="Rosella, Laura C" uniqKey="Rosella L" first="Laura C" last="Rosella">Laura C. Rosella</name></author><author><name sortKey="Stukel, Therese A" sort="Stukel, Therese A" uniqKey="Stukel T" first="Therese A" last="Stukel">Therese A. Stukel</name></author><author><name sortKey="Crowcroft, Natasha S" sort="Crowcroft, Natasha S" uniqKey="Crowcroft N" first="Natasha S" last="Crowcroft">Natasha S. Crowcroft</name></author><author><name sortKey="Mcgeer, Allison J" sort="Mcgeer, Allison J" uniqKey="Mcgeer A" first="Allison J" last="Mcgeer">Allison J. Mcgeer</name></author><author><name sortKey="Zinman, Lorne" sort="Zinman, Lorne" uniqKey="Zinman L" first="Lorne" last="Zinman">Lorne Zinman</name></author><author><name sortKey="Deeks, Shelley L" sort="Deeks, Shelley L" uniqKey="Deeks S" first="Shelley L" last="Deeks">Shelley L. Deeks</name></author></analytic><series><title level="j">The Lancet. Infectious diseases</title><idno type="eISSN">1474-4457</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Canada (epidemiology)</term><term>Female</term><term>Guillain-Barre Syndrome (chemically induced)</term><term>Guillain-Barre Syndrome (epidemiology)</term><term>Hospitalization</term><term>Humans</term><term>Incidence</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Seasons</term><term>Vaccination (adverse effects)</term><term>Vaccination (statistics & numerical data)</term><term>Vaccines, Inactivated (adverse effects)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada (épidémiologie)</term><term>Facteurs de risque</term><term>Femelle</term><term>Grippe humaine ()</term><term>Hospitalisation</term><term>Humains</term><term>Incidence</term><term>Jeune adulte</term><term>Mâle</term><term>Saisons</term><term>Sujet âgé</term><term>Syndrome de Guillain-Barré ()</term><term>Syndrome de Guillain-Barré (épidémiologie)</term><term>Vaccination ()</term><term>Vaccination (effets indésirables)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins inactivés (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Inactivated</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Guillain-Barre Syndrome</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccination</term><term>Vaccins antigrippaux</term><term>Vaccins inactivés</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Guillain-Barre Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term><term>Syndrome de Guillain-Barré</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Female</term><term>Hospitalization</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term><term>Seasons</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs de risque</term><term>Femelle</term><term>Grippe humaine</term><term>Hospitalisation</term><term>Humains</term><term>Incidence</term><term>Jeune adulte</term><term>Mâle</term><term>Saisons</term><term>Sujet âgé</term><term>Syndrome de Guillain-Barré</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The possible risk of Guillain-Barré syndrome from influenza vaccines remains a potential obstacle to achieving high vaccination coverage. However, influenza infection might also be associated with Guillain-Barré syndrome. We aimed to assess the risk of Guillain-Barré syndrome after seasonal influenza vaccination and after influenza-coded health-care encounters.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We used the self-controlled risk interval design and linked universal health-care system databases from Ontario, Canada, with data obtained between 1993 and 2011. We used physician billing claims for influenza vaccination and influenza-coded health-care encounters to ascertain exposures. Using fixed-effects conditional Poisson regression, we estimated the relative incidence of hospitalisation for primary-coded Guillain-Barré syndrome during the risk interval compared with the control interval.</p></div><div type="abstract" xml:lang="en"><p><b>FINDINGS</b></p><p>We identified 2831 incident admissions for Guillain-Barré syndrome; 330 received an influenza vaccine and 109 had an influenza-coded health-care encounter within 42 weeks before hospitalisation. The risk of Guillain-Barré syndrome within 6 weeks of vaccination was 52% higher than in the control interval of 9-42 weeks (relative incidence 1·52; 95% CI 1·17-1·99), with the greatest risk during weeks 2-4 after vaccination. The risk of Guillain-Barré syndrome within 6 weeks of an influenza-coded health-care encounter was greater than for vaccination (15·81; 10·28-24·32). The attributable risks were 1·03 Guillain-Barré syndrome admissions per million vaccinations, compared with 17·2 Guillain-Barré syndrome admissions per million influenza-coded health-care encounters.</p></div><div type="abstract" xml:lang="en"><p><b>INTERPRETATION</b></p><p>The relative and attributable risks of Guillain-Barré syndrome after seasonal influenza vaccination are lower than those after influenza illness. Patients considering immunisation should be fully informed of the risks of Guillain-Barré syndrome from both influenza vaccines and influenza illness.</p></div><div type="abstract" xml:lang="en"><p><b>FUNDING</b></p><p>Canadian Institutes of Health Research.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23810252</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2014</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4457</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Lancet. Infectious diseases</Title><ISOAbbreviation>Lancet Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.</ArticleTitle><Pagination><MedlinePgn>769-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1473-3099(13)70104-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1473-3099(13)70104-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The possible risk of Guillain-Barré syndrome from influenza vaccines remains a potential obstacle to achieving high vaccination coverage. However, influenza infection might also be associated with Guillain-Barré syndrome. We aimed to assess the risk of Guillain-Barré syndrome after seasonal influenza vaccination and after influenza-coded health-care encounters.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used the self-controlled risk interval design and linked universal health-care system databases from Ontario, Canada, with data obtained between 1993 and 2011. We used physician billing claims for influenza vaccination and influenza-coded health-care encounters to ascertain exposures. Using fixed-effects conditional Poisson regression, we estimated the relative incidence of hospitalisation for primary-coded Guillain-Barré syndrome during the risk interval compared with the control interval.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We identified 2831 incident admissions for Guillain-Barré syndrome; 330 received an influenza vaccine and 109 had an influenza-coded health-care encounter within 42 weeks before hospitalisation. The risk of Guillain-Barré syndrome within 6 weeks of vaccination was 52% higher than in the control interval of 9-42 weeks (relative incidence 1·52; 95% CI 1·17-1·99), with the greatest risk during weeks 2-4 after vaccination. The risk of Guillain-Barré syndrome within 6 weeks of an influenza-coded health-care encounter was greater than for vaccination (15·81; 10·28-24·32). The attributable risks were 1·03 Guillain-Barré syndrome admissions per million vaccinations, compared with 17·2 Guillain-Barré syndrome admissions per million influenza-coded health-care encounters.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The relative and attributable risks of Guillain-Barré syndrome after seasonal influenza vaccination are lower than those after influenza illness. Patients considering immunisation should be fully informed of the risks of Guillain-Barré syndrome from both influenza vaccines and influenza illness.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Canadian Institutes of Health Research.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institute for Clinical Evaluative Sciences, Toronto, Canada. jeff.kwong@utoronto.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasa</LastName><ForeName>Priya P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Campitelli</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Hawken</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Kumanan</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rosella</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Stukel</LastName><ForeName>Therese A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Crowcroft</LastName><ForeName>Natasha S</ForeName><Initials>NS</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>Allison J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Shelley L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Lancet Infect Dis</MedlineTA><NlmUniqueID>101130150</NlmUniqueID><ISSNLinking>1473-3099</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2013 Sep;13(9):730-1</RefSource><PMID Version="1">23810251</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2014 May;14(5):368-9</RefSource><PMID Version="1">24758989</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2014 May;14(5):368</RefSource><PMID Version="1">24758990</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Infect Dis. 2014 May;14(5):369-70</RefSource><PMID Version="1">24758991</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23810252</ArticleId><ArticleId IdType="pii">S1473-3099(13)70104-X</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(13)70104-X</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Campitelli, Michael A" sort="Campitelli, Michael A" uniqKey="Campitelli M" first="Michael A" last="Campitelli">Michael A. Campitelli</name><name sortKey="Crowcroft, Natasha S" sort="Crowcroft, Natasha S" uniqKey="Crowcroft N" first="Natasha S" last="Crowcroft">Natasha S. Crowcroft</name><name sortKey="Deeks, Shelley L" sort="Deeks, Shelley L" uniqKey="Deeks S" first="Shelley L" last="Deeks">Shelley L. Deeks</name><name sortKey="Hawken, Steven" sort="Hawken, Steven" uniqKey="Hawken S" first="Steven" last="Hawken">Steven Hawken</name><name sortKey="Mcgeer, Allison J" sort="Mcgeer, Allison J" uniqKey="Mcgeer A" first="Allison J" last="Mcgeer">Allison J. Mcgeer</name><name sortKey="Rosella, Laura C" sort="Rosella, Laura C" uniqKey="Rosella L" first="Laura C" last="Rosella">Laura C. Rosella</name><name sortKey="Stukel, Therese A" sort="Stukel, Therese A" uniqKey="Stukel T" first="Therese A" last="Stukel">Therese A. Stukel</name><name sortKey="Vasa, Priya P" sort="Vasa, Priya P" uniqKey="Vasa P" first="Priya P" last="Vasa">Priya P. Vasa</name><name sortKey="Wilson, Kumanan" sort="Wilson, Kumanan" uniqKey="Wilson K" first="Kumanan" last="Wilson">Kumanan Wilson</name><name sortKey="Zinman, Lorne" sort="Zinman, Lorne" uniqKey="Zinman L" first="Lorne" last="Zinman">Lorne Zinman</name></noCountry><country name="Canada"><noRegion><name sortKey="Kwong, Jeffrey C" sort="Kwong, Jeffrey C" uniqKey="Kwong J" first="Jeffrey C" last="Kwong">Jeffrey C. Kwong</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000328 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000328 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeCanadaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23810252
|texte= Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23810252" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV3
| This area was generated with Dilib version V0.6.35. |  |